Premier Path Wealth Partners LLC Has $1.24 Million Stock Holdings in Becton, Dickinson and Company (NYSE:BDX)

Premier Path Wealth Partners LLC raised its holdings in Becton, Dickinson and Company (NYSE:BDX) by 4.8% in the 4th quarter, according to the company in its most recent filing with the SEC. The firm owned 5,473 shares of the medical instruments supplier’s stock after acquiring an additional 251 shares during the quarter. Premier Path Wealth Partners LLC’s holdings in Becton, Dickinson and Company were worth $1,242,000 as of its most recent SEC filing.

Several other large investors have also recently modified their holdings of BDX. MQS Management LLC acquired a new stake in shares of Becton, Dickinson and Company in the second quarter valued at about $485,000. Ieq Capital LLC increased its position in Becton, Dickinson and Company by 22.0% during the 2nd quarter. Ieq Capital LLC now owns 9,238 shares of the medical instruments supplier’s stock valued at $2,159,000 after purchasing an additional 1,668 shares during the period. Benjamin F. Edwards & Company Inc. raised its holdings in Becton, Dickinson and Company by 2.0% during the 2nd quarter. Benjamin F. Edwards & Company Inc. now owns 98,720 shares of the medical instruments supplier’s stock worth $23,072,000 after purchasing an additional 1,931 shares during the last quarter. Canada Pension Plan Investment Board raised its holdings in Becton, Dickinson and Company by 55.7% during the 2nd quarter. Canada Pension Plan Investment Board now owns 436,183 shares of the medical instruments supplier’s stock worth $101,940,000 after purchasing an additional 155,990 shares during the last quarter. Finally, Callan Capital LLC boosted its stake in shares of Becton, Dickinson and Company by 0.9% in the 2nd quarter. Callan Capital LLC now owns 7,100 shares of the medical instruments supplier’s stock valued at $1,659,000 after purchasing an additional 61 shares during the last quarter. Institutional investors own 86.97% of the company’s stock.

Insider Transactions at Becton, Dickinson and Company

In related news, EVP Shana Carol Neal sold 788 shares of Becton, Dickinson and Company stock in a transaction that occurred on Tuesday, January 7th. The shares were sold at an average price of $235.00, for a total value of $185,180.00. Following the sale, the executive vice president now owns 16,201 shares of the company’s stock, valued at approximately $3,807,235. The trade was a 4.64 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, EVP Michael David Garrison sold 2,838 shares of the company’s stock in a transaction that occurred on Thursday, December 19th. The shares were sold at an average price of $223.33, for a total value of $633,810.54. Following the completion of the transaction, the executive vice president now owns 6,141 shares in the company, valued at approximately $1,371,469.53. The trade was a 31.61 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 8,747 shares of company stock worth $1,949,520 in the last ninety days. Company insiders own 0.36% of the company’s stock.

Analyst Ratings Changes

Several research firms have recently weighed in on BDX. StockNews.com lowered Becton, Dickinson and Company from a “buy” rating to a “hold” rating in a research report on Wednesday, December 18th. Citigroup raised shares of Becton, Dickinson and Company from a “neutral” rating to a “buy” rating and increased their price objective for the stock from $255.00 to $275.00 in a research report on Tuesday, October 1st. Finally, Evercore ISI boosted their target price on Becton, Dickinson and Company from $286.00 to $290.00 and gave the company an “outperform” rating in a research report on Tuesday, October 1st. One equities research analyst has rated the stock with a hold rating and six have given a buy rating to the stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $283.50.

Becton, Dickinson and Company Stock Up 0.5 %

Becton, Dickinson and Company stock opened at $237.57 on Friday. Becton, Dickinson and Company has a fifty-two week low of $218.75 and a fifty-two week high of $248.42. The company has a debt-to-equity ratio of 0.69, a quick ratio of 0.74 and a current ratio of 1.17. The firm’s 50-day simple moving average is $226.95 and its 200 day simple moving average is $232.53. The stock has a market cap of $68.90 billion, a PE ratio of 40.00, a price-to-earnings-growth ratio of 1.69 and a beta of 0.39.

Becton, Dickinson and Company (NYSE:BDX) last announced its earnings results on Thursday, November 7th. The medical instruments supplier reported $3.81 earnings per share for the quarter, topping analysts’ consensus estimates of $3.77 by $0.04. The firm had revenue of $5.44 billion for the quarter, compared to the consensus estimate of $5.38 billion. Becton, Dickinson and Company had a return on equity of 14.89% and a net margin of 8.55%. The company’s revenue was up 6.9% compared to the same quarter last year. During the same quarter in the previous year, the business earned $3.42 EPS. Research analysts predict that Becton, Dickinson and Company will post 14.43 EPS for the current fiscal year.

Becton, Dickinson and Company Increases Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Tuesday, December 31st. Shareholders of record on Monday, December 9th were paid a $1.04 dividend. This represents a $4.16 dividend on an annualized basis and a yield of 1.75%. The ex-dividend date of this dividend was Monday, December 9th. This is an increase from Becton, Dickinson and Company’s previous quarterly dividend of $0.95. Becton, Dickinson and Company’s dividend payout ratio is 70.03%.

Becton, Dickinson and Company Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.